Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ).
Shanghai Pharmaceuticals Holding has secured board approval to renew its sales and procurement framework arrangement with substantial shareholder Yunnan Baiyao for another year, setting up a 2026 framework under which the two groups will continue to trade a broad range of medicines, medical devices, healthcare products, food products, and TCM-related items. Although the 2026 framework agreement is not yet executed, it will run from 1 January to 31 December 2026 and allows members of both groups to sign individual implementation contracts within annual caps, with the transactions classified as continuing connected transactions under Hong Kong listing rules, triggering reporting, annual review, and announcement obligations but exempting the company from circular and independent shareholders’ approval requirements.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a major Chinese pharmaceutical group engaged in the production and distribution of medicines, medical devices, healthcare products, food products, and traditional Chinese medicine (TCM) decoction pieces and ingredients. The company operates across manufacturing and distribution segments, supplying both self-produced products and those for which it acts as a main distributor in mainland China and overseas markets.
YTD Price Performance: -4.58%
Average Trading Volume: 2,747,135
Technical Sentiment Signal: Sell
Current Market Cap: HK$66.02B
Learn more about 2607 stock on TipRanks’ Stock Analysis page.